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Abstract
Background: Clinical deterioration on drug therapy for tuberculosis is a common cause of hospital admission in Africa.
Potential causes for clinical deterioration in settings of high HIV-1 prevalence include drug resistant Mycobacterium
tuberculosis (M.tb), co-morbid illnesses, poor adherence to therapy, tuberculosis associated-immune reconstitution
inflammatory syndrome (TB-IRIS) and subtherapeutic antitubercular drug levels. It is important to derive a rapid diagnostic
work-up to determine the cause of clinical deterioration as well as specific management to prevent further clinical
deterioration and death. We undertook this study among tuberculosis (TB) patients referred to an adult district level hospital
situated in a high HIV-1 prevalence setting to determine the frequency, reasons and outcome for such clinical deterioration.
Method: A prospective observational study conducted during the first quarter of 2007. We defined clinical deterioration as
clinical worsening or failure to stabilise after 14 or more days of antitubercular treatment, resulting in hospital referral. We
collected data on tuberculosis diagnosis and treatment, HIV-1 status and antiretroviral treatment, and investigated reasons
for clinical deterioration as well as outcome.
Results: During this period, 352 TB patients met inclusion criteria; 296 were admitted to hospital accounting for 17% of total
medical admissions (n = 1755). Eighty three percent of TB patients (291/352) were known to be HIV-1 co-infected with a
median CD4 count of 89cells/mm3 (IQR 38–157). Mortality among TB patients admitted to hospital was 16% (n = 48). The
median duration of hospital admission was 9.5 days (IQR 4–18), longer than routine in this setting (4 days). Among patients
in whom HIV-1 status was known (n = 324), 72% of TB patients (n = 232) had an additional illness to tuberculosis; new AIDS
defining illnesses (n = 80) were the most frequent additional illnesses (n = 208) in HIV-1 co-infected patients (n = 291).
Rifampin-resistant M.tb (n = 41), TB-IRIS (n = 51) and drug resistant bacterial infections (n = 12) were found in 12%, 14% and
3.4% of the 352 cases, respectively.
Interpretation: In our setting, new AIDS defining illnesses, drug resistant M.tb and other drug resistant bacteria are
important reasons for clinical deterioration in HIV-1 co-infected patients receiving antitubercular treatment. HIV-1 co-
infected patients may be at increased risk of acquiring nosocomial drug resistant pathogens because profound immune
suppression results in co-morbid illnesses that require prolonged inpatient admissions. Routine infection control is essential
and needs to be strengthened in our setting.
Citation: Pepper DJ, Rebe K, Morroni C, Wilkinson RJ, Meintjes G (2009) Clinical Deterioration during Antitubercular Treatment at a District Hospital in South
Africa: The Importance of Drug Resistance and AIDS Defining Illnesses. PLoS ONE 4(2): e4520. doi:10.1371/journal.pone.0004520
Editor: Keertan Dheda, University of Cape Town, United Kingdom
Received October 11, 2008; Accepted January 13, 2009; Published February 20, 2009
Copyright:  2009 Pepper et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The Perinatal HIV Research Unit from the United States Agency for International Development (USAID) and PEPFAR supports Dominique Pepper. The
Wellcome Trust (072070) and the Medical Research Council (UK) support Robert Wilkinson. The Wellcome Trust (081667) supports Graeme Meintjes. The contents
are the responsibility of the authors and do not necessarily reflect the views of USAID or the United States Government. None of the funders had any role in
design and conduct of the study; collection, management, analysis, and interpretation of the data; nor preparation, review, or approval of the manuscript. This
research paper is made possible by funding through the Perinatal HIV-1 Research Unit affiliated with the United States Agency for International Development
(USAID) and PEPFAR.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: dominiquepepper@gmail.com
Introduction
In 2007, of an estimated total population of 47.9 million people
in South Africa, an estimated 5.7 million were infected with HIV-1
and 0.35 million died from AIDS-related illnesses [1]. In 2006, the
annual tuberculosis incidence rate was estimated to be 628 cases
per 100,000 of the population per annum [2]. The two pandemics
of tuberculosis and HIV-1 fuel each other. The annual incidence
of tuberculosis disease doubles within the first year of HIV-1
infection[3] and may reach 30% per annum in the profoundly
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immune-suppressed [4]. Likewise, tuberculosis disease synergisti-
cally accelerates the progression of HIV-1 infection to Acquired
Immune Deficiency Syndrome (AIDS) by inciting viral replication
in immunologically activated CD4 cells [5,6,7]. In South Africa
more than half of tuberculosis (TB) patients tested for HIV-1 are
seropositive[8] and very many of the 22.5 million HIV-1
seropositive people residing in Sub-Saharan Africa are co-infected
with M. tuberculosis (M.tb) [9].
Tuberculosis and HIV-1 control programmes in Africa are
complicated by the increasing emergence of drug resistant M.tb,
which can be associated with a very poor outcome and thus
adversely affect overall tuberculosis control programme perfor-
mance. In 2006, 44 HIV-1 seropositive patients died a median
of 16 days after obtaining a specimen that cultured extensively
drug resistant (XDR-) M.tb in a rural area of Kwa-Zulu Natal
[10]. Nosocomial exogenous re-infection was implicated as two-
thirds of patients were recently hospitalised before the diagnosis
of XDR-tuberculosis and genotyping of isolates showed that
85% of patients were infected with a genetically similar isolate,
belonging to the KZN family of strains. Focusing on patients
worsening or not stabilising on antitubercular treatment is
valuable in sentinel assessment of drug resistant M.tb transmis-
sion and mortality. Patients deteriorating on antitubercular
treatment constitute a clinical subgroup in which one would
predict higher rates of MDR- and XDR- M.tb. However, these
patients may also deteriorate due to other reasons. Reasons for
clinical deterioration[11] and death in patients on antitubercu-
lar treatment include co-morbid conditions [12,13,14,15],
exogenous re-infection or endogenous development of drug
resistant M.tb [10,16], tuberculosis associated-immune reconsti-
tution inflammatory syndrome (TB-IRIS)[17,18] and drug
toxicities from treatment for tuberculosis, HIV-1 and/or
concurrent opportunistic infections [19,20,21,22]. Other causes
are an incorrect diagnosis of tuberculosis, a paradoxical
tuberculosis reaction (if not receiving antiretroviral therapy),
poor adherence [23], incorrect antitubercular treatment,
malabsorption of antitubercular treatment [24], as well as
malabsorption of antibiotic drugs and subsequently altered
pharmacokinetics (particularly in HIV-1 infected individuals
with gastrointestinal problems). It is important to derive a rapid
diagnostic work-up to determine cause of clinical deterioration
as well as specific management to prevent further clinical
deterioration and death.
This study aimed to determine which of these reasons for
clinical deterioration on antitubercular treatment was most
significant at an exceptionally busy urban district hospital situated
in an area of high HIV-1 prevalence.
Methods
Setting
A prospective observational study conducted from 9 January to
8 April 2007 at GF Jooste Hospital (GFJH). GFJH is an urban
200-bed adult (.15 years age) district hospital in Cape Town,
South Africa that serves approximately 1.3 million people and
receives 8,000 referrals per month[25] from 30 primary care
clinics.
The national tuberculosis programme manages new tuberculo-
sis cases with 6 months treatment (isoniazid, rifampin, pyrazin-
amide, and ethambutol [HRZE] for 2 months followed by HR for
4 months [2HRZE/4HR]). The retreatment regimen adds
streptomycin (S) as follows 2HRZES/1HRZE/5HRE. New
tuberculosis cases do not routinely have tuberculosis drug
susceptibility testing (DST) performed. Retreatment cases and
patients not responding to antitubercular treatment may have
DST performed.
Over 10,000 people have initiated combination antiretroviral
treatment (cART) within the catchment area of GFJH (Meg Osler,
Provincial Government of the Western Cape- personal commu-
nication). First-line cART in South Africa is stavudine (d4T),
lamivudine (3TC) and either nevirapine or efavirenz (NVP, EFZ).
EFZ is preferred in patients receiving rifampin-based antituber-
cular treatment. Patients with a CD4 count less than 200cells/
mm3 and/or a history of a WHO stage 4 illness are eligible to
commence cART [26]. In patients diagnosed with tuberculosis,
cART is deferred if there is no history of a WHO Stage 4 illness
and the CD4 count is greater than 200 cells/mm3. If there is a
history of a WHO Stage 4 illness and/or the CD4 count is less
than 200 cells/mm3 cART is commenced 2 months after initiating
antitubercular treatment. If the CD4 count is less than 50 cells/
mm3 or a serious HIV-1 related illness exists, cART can be
commenced two weeks after initiating antitubercular treatment
[26].
Study procedures
Eligibility. Adult patients (.15 years) who received $14days
antitubercular treatment within GFJH’s catchment area and were
referred by a medical doctor or nurse to the Emergency
Department or Infectious Diseases Unit were assessed. Prior to
referral, patients were diagnosed with tuberculosis at any of the 12
tuberculosis clinics within the catchment population of GF Jooste
Hospital. If they deteriorated and were referred to GF Jooste
Hospital they underwent renewed/repeated diagnostic procedures
to either confirm tuberculosis disease (if previously
microbiologically unconfirmed) and to exclude drug resistant
M.tb. Patients were eligible if clinical worsening or failure to
stabilise on therapy was confirmed on clinical assessment by a
medical doctor at GFJH.
Tuberculosis diagnosis and referral. Microbiological
confirmation of tuberculosis disease was defined as a specimen
that cultured M.tb and/or was smear positive for acid-fast bacilli
and that was obtained from a patient with symptoms and signs of
tuberculosis [26]. An empiric diagnosis of tuberculosis was defined
as follows: antitubercular treatment was initiated when the
tuberculosis specimen was both smear negative for acid fast
bacilli and culture negative or pending for M.tb but the South
African National Tuberculosis Control Programme’s case
definitions for smear-negative and extra-pulmonary tuberculosis
were fulfilled [26]. Patients commenced antitubercular treatment
at their tuberculosis clinic and if they deteriorated or did not
improve on treatment they were referred to our hospital for
assessment.
Data collection. Clinical data regarding tuberculosis
diagnosis, antitubercular treatment, HIV-1 status and
antiretroviral therapy were recorded. Reasons for clinical
deterioration were determined by clinical assessment and
laboratory investigations performed by medical staff (doctors)
working in the Emergency Department and Infectious Diseases
Unit. All TB patients admitted to hospital were assessed by a
specialist physician and reviewed weekly during inpatient stay by
an Infectious Diseases physician. Investigations performed were
according to clinical presentation and included C-reactive protein,
full blood count (also called complete blood cell count), urea and
electrolytes, serological and blood culture investigations.
Specimens for tuberculosis microscopy, culture and sensitivity
included sputum, pleural fluid, lymph node aspirates, ascitic fluid
or cerebrospinal fluid (CSF). Chest radiography and computerised
tomographic scanning were performed as indicated. Investigations
Deterioration on TB Therapy
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also included sputum direct immuno-fluorescent antigen tests
(DFAT) for Pneumocystis jiroveci pneumonia, CSF bacterial and
fungal cultures and stool microscopy for coccidian parasites and
culture for bacteria. All patients who develop drug-induced hepatitis
are initially managed as inpatients according to a standardised
protocol. The tuberculosis diagnosis is re-evaluated by reviewing
results of all tuberculosis specimens. After clinical stabilisation and
return to baseline of liver function tests, patients are carefully
monitored and antitubercular drugs are sequentially rechallenged in
cases of non-life threatening hepatitis and microbiologically proven
tuberculosis. In severe cases (coagulopathy or encephalopathy), re-
challenge of antitubercular treatment is not attempted. Instead,
patients are treated with an alternative antitubercular regimen that
does not involve rechallenge.
Tuberculosis diagnostics. The National Health Laboratory
Services performed tuberculosis diagnostics. Ziehl-Nielsen staining
was performed within 24 hours on all tuberculosis specimens,
while auramine staining was performed on broth culture isolates.
M.tb liquid culture, solid media susceptibility testing for isoniazid
and rifampin, and quality assurance were performed as described
elsewhere [27]. According to provincial protocol ethambutol
(7.5 mcg/mL), ethionamide (20 mcg/ml), amikacin (30 mcg/mL),
kanamycin (6 mcg/mL) and ofloxacin (2 mcg/mL) susceptibility
testing was only performed in patients with rifampin resistance.
Susceptibility testing to pyrazinamide, streptomycin and the
remaining three second line drugs—terizidone, capreomycin,
para-aminosalicylic acid— was not performed.
Definitions. Positive cultures for M.tb were categorised on
the basis of drug susceptibility as: (i) susceptible to both isoniazid
and rifampin; (ii) mono-resistant to rifampin; (iii) resistant to at
least isoniazid and rifampin (MDR- M.tb); (iv) resistant to
isoniazid, rifampin and either resistance to an injectable agent
(amikacin or kanamycin) or ofloxacin (pre-XDR M.tb); and
(v)resistant to isoniazid, rifampin, ofloxacin, and an injectable
agent or ofloxacin (XDR M.tb) ‘Rifampin resistance’ was defined
as any resistance to rifampin and included rifampin mono-
resistant-, MDR- , XDR- and pre-XDR- M.tb [28].
Extended-spectrum beta lactamase (ESBL) producing bacteria
were defined as bacteria having clavulanate-inhibited transferable
enzymes able to hydrolyse third and fourth generation cephalo-
sporins while methicillin resistant Staphylococcus aureus (MRSA) had
an oxacillin minimum inhibitory concentration (MIC) $4 mg/l.
TB-IRIS was defined according to a clinical case definition [29].
Adherence to antitubercular treatment was assessed by patient
report, tuberculosis clinic cards (upon which daily doses taken are
recorded) and/or collateral information from the health care
worker at the tuberculosis clinic. No specific criteria were utilised
but if no subsequent cause for deterioration was found and the
patient had ,80% adherence, the patient was assessed as having
poor adherence. An additional illness to tuberculosis was defined
as a second illness in patients where the initial tuberculosis
diagnosis was confirmed by smear, culture and/or initial clinical
response to antitubercular treatment where smear-negative and/
or extrapulmonary tuberculosis was observed. It excluded poor
adherence to antitubercular treatment, rifampin resistant M.tb,
TB-IRIS or a paradoxical tuberculosis reaction. The use of
concomitant cART distinguishes IRIS from a paradoxical TB
reaction; IRIS occurs in patients receiving cART while paradox-
ical TB reaction occurs in the absence of cART. An alternate
illness to tuberculosis was diagnosed when a clinical illness initially
diagnosed as tuberculosis was not confirmed by smear or culture,
there was no clinical response to antitubercular treatment and
evidence of an alternate illness to explain the clinical presentation
and course was found.
Outcomes. The primary outcome of the study was reason for
clinical deterioration despite antitubercular treatment, with a
specific focus on the proportion of rifampin resistant M.tb. The
secondary outcome was outcome of admission.
Analysis. Data analysis was conducted using STATA-10
(Stata Corporation, College Station, Texas). Descriptive statistics
were employed for basic characterization of variables. Wilcoxon
rank-sum tests to compare medians, and Fisher’s exact test of
probability to compare proportions were used, as appropriate, to
identify associations.
The Research Ethics Committee of the University of Cape
Town approved the study (REF: 239/2007).
Results
Characterization of cohort
Three hundred and fifty-two patients met study inclusion criteria
during the 3-month period. At initial tuberculosis diagnosis, 163
(46%) had pulmonary tuberculosis, 67 (19%) had extra-pulmonary
tuberculosis and 122 (35%) had combined pulmonary and
extrapulmonary tuberculosis. The median duration from initiation
of antitubercular treatment to clinical presentation was 92.5 days
(interquartile range, IQR 43–149). Eighty-four percent of TB
patients (n= 296) required hospital admission for a median duration
of 9.5 days (IQR 4–18). Admissions for patients deteriorating on
antitubercular treatment accounted for 17% medical admissions
(296/1,755) during the three-month study period.
Eighty-three percent of TB patients (n = 291) were HIV-1
seropositive and 9% (n= 33) were HIV-1 seronegative (Figure 1).
In 8% (n= 28), HIV-1 testing was not performed prior to referral
or during investigation at GFJH; reasons included: not offered
voluntary counselling and testing (VCT), VCT declined or too sick
to obtain informed consent. Baseline features of TB patients
stratified by HIV-1 status are shown in Table 1. HIV-1
seropositive TB patients were more frequently female, and less
likely to have a past history of tuberculosis or microbiological
confirmation (p#0.01). The median CD4 count among HIV-1
seropositive TB patients was 89 cells/mm3 (n= 270). Of 255
patients who met the South African Department of Health criteria
to receive cART [26], 122 (48%) were receiving this treatment.
Final diagnoses
An additional illness to tuberculosis was detected in 72% of TB
patients (n = 232) with known HIV-1 seropositive and HIV-1
seronegative status combined (n = 324) (Figure 1). Rifampin-
resistant M.tb (n = 41), TB-IRIS (n= 51) and other drug resistant
bacterial infections (n = 12) were diagnosed. Twenty-four TB
patients had poor adherence to antitubercular treatment and
fifteen patients had an alternate illness to tuberculosis.
Additional illness to tuberculosis. Additional illnesses to
tuberculosis differed according to HIV-1 status (Figure 1). In the
HIV-1 seropositive group (Table 2), new AIDS defining illnesses
(n = 80), bacterial infection (n= 53), gastroenteritis (n = 37) and
drug toxicity to cART, antitubercular, antibiotic or antineoplastic
medications (n = 35) were most frequent. In the HIV-1
seronegative group, complications of tuberculosis, or its therapy
(n= 7), and bacterial infection (n = 6) were most common.
Antitubercular drug resistance. Rifampin resistance M.tb
was found in 41 TB patients. Eight had rifampin mono-resistant
M.tb, 24 had MDR- M.tb, four had pre-XDR- M.tb and five had
XDR- M.tb. Extended sensitivity testing was performed on only 15
(37%) of the 41 rifampin resistant tuberculosis cases; one third (5/
15) of these patients had XDR- M.tb, while a further 27% (4/15)
had pre-XDR- M.tb.
Deterioration on TB Therapy
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Figure 1. * Many patients had .1 cause for clinical deterioration, particularly additional illnesses. HIV-1 = human immunodeficiency
virus, M.tb =Mycobacterium tuberculosis, TB-IRIS = tuberculosis associated-immune reconstitution inflammatory syndrome, Paradoxical tuberculosis
reaction = initial clinical improvement with subsequent recurrence of tuberculosis clinical features but no evidence of drug resistant tuberculosis/or
any other illness and patient not receiving antiretroviral therapy, MRSA=methicillin resistant Staphylococcus Aureus, ESBL = extended spectrum beta
lactamase producing organism.
doi:10.1371/journal.pone.0004520.g001
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Figure 2 depicts TB culture results at initial TB diagnosis (left
figure) and at subsequent deterioration (right figure). At initial
tuberculosis diagnosis specimens were sent for tuberculosis culture
in 237/352 (67%) patients, with 131 TB patients having a positive
culture (Figure 2). Of 131 patients that cultured M.tb from
specimens at initial tuberculosis diagnosis, 46 (35%) did not have
drug susceptibility testing performed. Of the 85 TB patients who
did have tuberculosis drug sensitivity analysis at diagnosis, 12
(14%) cultured rifampin resistant M.tb and 73 patients (86%)
cultured rifampin sensitive M.tb.
At clinical deterioration specimens were sent for tuberculosis
culture in 234/352 (66%) patients, with 69 patients culturing M.tb.
Of these 69 patients, 4 (6%) did not have drug susceptibility testing
performed. Of 65 patients who did have antitubercular drug
sensitivity testing at clinical deterioration, 35 patients (54%)
cultured rifampin resistant M.tb and 30 patients (46%) cultured
rifampin sensitive M.tb.
Thus, at clinical deterioration, 29 new cases of rifampin resistant
tuberculosis were diagnosed. These 29 cases had the following
tuberculosis results at initial diagnosis: 6 M.tb sensitive to rifampin
and isoniazid, 4 M.tb no sensitivities requested, and 3 no
mycobacteria cultured. Sixteen of these 29 new cases of rifampin
resistant tuberculosis had no tuberculosis culture sent at initial
tuberculosis diagnosis.
Of 73 patients who had rifampin sensitive M.tb at initial
tuberculosis diagnosis, eight (11%) cultured rifampin resistant M.tb
at clinical deterioration. Of these eight, 2 patients cultured
rifampin-mono-resistant M.tb, 5 MDR- M.tb and 1 XDR- M.tb, 12
to 419 days following the start of antitubercular treatment. Thirty
seven percent of patients with rifampin resistant M.tb (15/41) are
known to have died within six months of initial assessment at
GFJH. The median duration from assessment to death was 28
days (IQR 11–72).
Forty-one patients who at initial TB diagnosis were culture
negative (n = 11) or no culture was sent (n = 30), subsequently
cultured M.tb at deterioration. In 11% (39/352) of cases, no
tuberculosis cultures were sent at initial tuberculosis diagnosis and
at clinical deterioration.
Extended spectrum beta lactamase producing organisms/
methicillin resistant Staphylococcus aureus. At clinical
deterioration, 214/352 (61%) TB patients had specimens sent for
bacterial culture (128 of these TB patients had blood cultures
performed). Of 214 TB patients that had $1 specimens sent for
bacterial culture, 35 (16%) cultured clinically significant organisms.
Cultured organisms and sites from which these specimens were
obtained are detailed in table 2.
Of 53 HIV-1 seropositive TB patients treated empirically for
bacterial infections (Figure 1), 32 had confirmatory cultures.
Twelve of these TB patients cultured either extended spectrum
beta lactamase (ESBL) producing organisms or methicillin
resistant Staph. aureus (MRSA) (Table 3). The median CD4 count
of these 12 TB patients was 57 cells/mm3 (IQR 21–80). Of nine
TB patients culturing ESBL organisms, five had intermediate or
high level resistance to amikacin while seven had high level
resistance to ciprofloxacin. All were sensitive to imipenem,
meropenem or piperacillin-tazobactam. Four TB patients had a
septic illness due to MRSA, all were sensitive to vancomycin. One
TB patient cultured both ESBL and MRSA organisms. Antibiotics
Table 1. Characteristics of patients deteriorating on
antitubercular treatment (N = 324) by HIV-1 status.
HIV-1 +ve HIV-1 2ve P-value
(n =291) (n =33)
Demographics
Male – N (%) 138 (47.4) 24 (72.7) 0.006
Median age – years (range) 34 (16–86) 37 (19–68) NS1
Basis of tuberculosis diagnosis
Smear +ve – N (%) 106 (36.4) 22 (66.7) 0.001
Smear 2ve/Culture +ve – N (%) 28 (9.6) 1 (3.0) NS
Empiric diagnosis – N (%)2 157 (54.0) 10 (30.3) 0.01
Previous tuberculosis
2n (%) 101 (34.7) 19 (57.6) 0.01
Admitted
2n (%) 238 (81.8) 31 (94.0) NS
Median duration – days (IQR3) 10 (4–18) 11 (5–22) NS
Outcome
Died as inpatient – N (%) 43 (14.8) 5 (15.2) NS
Illness contributory to death
Bacterial illness 12 1
Enteric illness 8 -
Pneumocystis jiroveci pneumonia 6 -
Venous thromboembolism 5 2
Drug side effects 3 -
Rifampin resistant-tuberculosis4 3 -
Kaposi sarcoma 2 -
Cryptococcal meningitis 2 -
Neurological TB-IRIS 2 -
Chronic renal failure - 1
Acute coronary syndrome - 1
1NS: not significant, p-value significant at p#0.05.
2i.e. No microbiological proof at commencement of tuberculosis treatment.
3Interquartile range.
4Rifampin resistant-tuberculosis =Mycobacterium tuberculosis, with resistance to
at least rifampin, cultured from a patient with clinical deterioration of
symptoms attributable to progressive tuberculosis disease.
doi:10.1371/journal.pone.0004520.t001
Table 2. Organisms cultured and sites from which they were
obtained*.
Organisms cultured n Site of cultured organisms n
Escheriae. coli 17 Blood 13
Klebsiella spp 5 Urine 10
Staphylococcus aureus 8 Soft tissue abscess 9
Proteus 3 Sputum 3
Acinetobacter 3 Ascitic fluid 2
Enterococcus 2 Faeces 1
Enterobacter 1
Haemophilus influenza 1
Streptococcus anginosus 1
Streptococcus pneumonia 1
Pseudomonas 1
Salmonella type C 1
*44 organisms were cultured from 38 sites from 35 patients: 3 patients cultured
MRSA from $2 sites, 5 patients cultured 2 clinically significant bacteria from a
single site.
doi:10.1371/journal.pone.0004520.t002
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administered to these 12 TB patients are shown in Table 3. Of
these 13 drug-resistant isolates, nine (69%) were drug resistant
bacteria cultured $48 hours after admission at GFJH (range 2–
21days) while four (31%) were cultured on the day of admission.
Six of the twelve (50%) TB patients were admitted to a hospital in
the month preceding this GFJH admission for a median duration
of 10 days (IQR 8–26). Nine TB patients (75%) with these
infections died with the median time from obtaining the specimen
to death being 10.5 days (IQR 6.3–14.5).
TB-IRIS. Fifty one (18%) of the 291 HIV-1 seropositive TB
patients were diagnosed with TB-IRIS. Their median CD4 count
nadir was 65 cells/mm3 (IQR 33–113). The median interval
between initiation of tuberculosis therapy and initiation of cART
was 69 days (IQR 35–94), and the median interval between cART
initiation and onset of TB-IRIS symptoms was 14 days (IQR 7–
24).
Alternate illness to tuberculosis. An alternate illness to
tuberculosis was found in 9% of patients (16/181) who started
empiric antitubercular treatment. In the HIV-1 infected group
(n = 12) alternate illnesses were predominantly new AIDS defining
illnesses including Kaposi’s sarcoma (n= 2), Pneumocystis jiroveci
pneumonia (n = 2) and non-Hodgkin’s lymphoma (n = 2).
Inpatient mortality
Inpatient mortality did not differ significantly according to HIV-
1 status (p = 0.566, Table 1). Inpatient HIV-1 seropositive deaths
(N= 43) were mainly due to bacterial infections (n = 12), new
AIDS defining illnesses (n = 10), enteric illnesses (n = 8), and
pulmonary embolism (n= 5).
An estimated 3500 patients start antitubercular treatment every
three months at public sector primary care tuberculosis clinics
within our catchment area (Judy Caldwell, Western Cape
Tuberculosis Control Programme- personal communication).
Private sector antitubercular treatment is not provided in our
catchment area. During the 3-month study period 352 patients
(10%, 95% confidence interval: 9–11%) deteriorated despite
antitubercular treatment and required referral to our facility.
Discussion
We undertook this study to investigate which reasons for clinical
deterioration on antitubercular treatment were most significant in
a resource-limited setting with a high prevalence of tuberculosis
HIV-1 co-infection in Cape Town, South Africa. Focusing on this
particular patient group may improve their outcomes and
contribute to a rational use of limited resources especially as in
our setting they account for 10% of patients started on
antitubercular treatment.
We found that drug resistant M.tb and drug resistant bacterial
infections were important reasons for clinical deterioration and
death. Additional illnesses to tuberculosis accounted for most
referrals, especially bacterial infections and new AIDS-defining
illneses. Our findings are best explained in the context of rigorous
admission criteria due to bed pressures at the 200-bed hospital;
only 7.5% of adult patients referred to the emergency department
are admitted to medical wards. Admission is prioritised for life-
threatening illnesses requiring intravenous fluids or intravenous
antibiotics (such as antibacterial or antifungal agents), drug
resistant M.tb requiring daily inpatient intramuscular amikacin
or kanamycin injections (while awaiting a bed at the nearby MDR-
tuberculosis hospital) or patients requiring monitored supervision
of antitubercular treatment because of severe disease. It is
inevitable that a larger contingent of patients with clinical
deterioration not meeting such strict admission criteria is not
referred to hospital for assessment. A prospective study is needed
to determine whether such a group exists, and if so whether the
causes for clinical deterioration differ.
Nearly one-sixth of our patients cultured either drug resistant
M.tb or other drug resistant bacterial infections. This has two
important implications. Firstly we have identified a clinical
subgroup of patients, namely patients deteriorating on antituber-
cular treatment, in whom the incidence of rifampin resistant
tuberculosis (8.2%, 95% confidence interval: 5–11%) is high
compared to the 2.5% of all tuberculosis cases reported to have
MDR-tuberculosis in South Africa [30]. Secondly, tuberculosis
Figure 2. TB=Tuberculosis, RS-TB= rifampin sensitive M. tuberculosis, RR-TB= rifampin resistant M. tuberculosis. 6 of 12 patients who
had rifampin resistant M. tuberculosis at initial tuberculosis diagnosis, re-cultured rifampin resistant M. tuberculosis at clinical deterioration. i.e. 29 new
cases of rifampin resistant M. tuberculosis were diagnosed at clinical deterioration, 8 of 73 patients who had rifampin sensitive M. tuberculosis at initial
tuberculosis diagnosis cultured rifampin resistant M. tuberculosis at clinical deterioration.
doi:10.1371/journal.pone.0004520.g002
Deterioration on TB Therapy
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HIV-1 co-infected patients in a hospital setting appear prone to
acquire drug resistant bacteria such as ESBL and MRSA
organisms. Studies need to be conducted at other health facilities
to determine whether similar causes for clinical deterioration exist.
Nosocomial acquisition of XDR- M.tb among HIV-1 infected
patients with a very poor outcome has recently been described in
South Africa [10]; the contribution to death by co-morbid HIV-1
associated illnesses, however, was not discussed in that report. Our
study suggests co-morbidities may play a role in the death of such
patients.
The evolution from isoniazid and rifampin sensitive M.tb to
rifampin mono-resistant-, MDR-, preXDR- M.tb and XDR- M.tb
in eight patients may be due to initial mixed M.tb strain infection
[31], exogenous re-infection with rifampin resistant M.tb [16] or
the rapid development of M.tb drug resistance mutations despite a
multidrug-regimen i.e. amplified drug resistance. Nosocomial re-
infection of HIV-1 seropositive patients with MDR- and XDR-
M.tb has been documented in both resource rich and resource
constrained settings [10,16]. The possibility that drug resistance
evolved rapidly in drug susceptible cases receiving optimal
treatment appears less likely based on clinical history and collateral
information regarding adherence obtained from tuberculosis
clinics and relatives. The decline in proportion of patients
culturing M.tb may reflect either efficacious antitubercular
treatment, inability of the patient to expectorate sputa for culture,
or difficulty obtaining a non-pulmonary specimen for culture.
Nosocomial acquisition of drug resistant bacteria is also
suggested by the temporal association between i) the timing of
specimens that cultured ESBL and MRSA organisms and ii) the
duration of current and previous hospital admissions. The
unavailability of appropriate antimicrobial agents likely contrib-
uted to the high mortality rate in these 12 HIV-1 seropositive TB
patients. At the time of the study, the standard regimen for
suspected nosocomial sepsis was amikacin and ceftriaxone in the
absence of renal impairment, and ciprofloxacin and ceftriaxone if
present. Vancomycin was available to treat MRSA. Because of our
study findings, ertapenem is now available.
The incidence of additional illnesses such as new AIDS defining
illnesses, bacterial infections and gastroenteritis is indicative of the
profound immune suppression in the HIV-1 infected group.
Multiple opportunistic infections occur simultaneously in AIDS
patients. A necropsy study of HIV-1 infected patients from Brazil
reported more than one post-mortem diagnosis in 52% of the
patients, and 48% had at least one AIDS-related disease not
suspected clinically [32]. These researchers recommended aggres-
sive investigation for infections and cancers in sick patients with
AIDS, particularly in those not responding to initial antimicrobial
therapy [32]. Bacterial infections and enteric illnesses were found
in 26% and 18% of HIV-1 infected patients, respectively, in our
study. Current provincial government protocols recommend
starting co-trimoxazole prophylaxis in all HIV-1 positive patients
one month after initiating antitubercular treatment in order to
differentiate between side effects from antitubercular treatment
and co-trimoxazole [26,33]. This would likely reduce bacterial
infections. Adherence to this recommendation was not assessed
and needs to be determined in future studies. Although only 48%
of patients eligible for cART were receiving cART at assessment
for deterioration, it is likely that some patients subsequently
initiated cART.
TB-IRIS was a final diagnosis in 18% (51/291) of HIV-1
seropositive patients. This probably reflects the high incidence of
disseminated tuberculosis and the relatively late initiation of cART
in profoundly immune suppressed HIV-1 patients in our setting.
TB-IRIS is more likely to occur in patients with a low baseline
CD4 count, a short duration between initiation of antitubercular
treatment and cART and disseminated tuberculosis [34,35,36].
Fifteen cases of venous thrombo-embolic disease (12 deep vein
thrombosis and 3 pulmonary embolus) were observed among this
cohort. HIV-1 and rifampin are postulated risk factors for venous
thrombo-embolic disease [37,38].
Both HIV-1 uninfected and infected patients had prolonged
admissions (9.5 days) compared to the typical duration of
admission at GFJH (4 days) [25]. Longer inpatient admissions
increase the risk of acquisition of nosocomial drug resistant
pathogens, particularly in immune-compromised patients.
Our study’s limitations relate fundamentally to its design within
routine care in an exceptionally busy setting. Studies based in
hospitals suffer referral bias and so the extent of the problem of
clinical deterioration during antitubercular treatment cannot be
precisely determined although is clearly very significant and likely
to impact adversely on overall national tuberculosis programme
success. The initial tuberculosis diagnosis was often defined by
clinical algorithm rather than bacterial culture and, even at clinical
deterioration, not all patients were sampled. Of all 352 TB patients
assessed at deterioration, 182 (52%) did not culture M.tb at both
tuberculosis diagnosis and at deterioration. Final diagnosis relied
on available diagnostic modalities, better than in many parts of
Africa but not state-of-the-art. Resistance to second line
antitubercular agents was not always assayed: thus our estimates
of pre-XDR and XDR- M.tb may be falsely low. 8% of patients
were not tested for HIV-1 infection. Genotyping of drug resistance
M.tb and other bacterial strains would have allowed us to better
assess the likelihood of nosocomial transmission. All these factors
have been considered in a clinic-based second study of this
problem that is currently in progress.
As a result of these findings, basic infection control measures
have been strengthened; extraction fans have been installed at
high congestion areas and natural ventilation is encouraged to
reduce M.tb transmission. N95 respirator masks are readily
available to patients, relatives and health care workers to reduce
aerosol transmission and infection of tuberculosis. Simple
architectural modifications in the hospital are currently underway
to further improve ventilation and reduce M.tb transmission risk.
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